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Vitiligo is a skin and hair disorder characterized by
circumscribed depigmented lesions due to lack of
melanocytes in the respective areas. It has been sug-
gested that vitiligo is caused by an autoimmune-
mediated destruction of melanocytes. Recently, the
presence of a high frequency of skin-homing melano-
cyte-speci®c cytotoxic T lymphocytes in the peri-
pheral blood of patients with vitiligo was reported.
Our study examines the frequency of melanocyte-
speci®c cytotoxic T lymphocytes in vitiligo patients
and its relationship to disease activity. Thirty-two
patients with moderate to active vitiligo and 17 con-
trol subjects were included. Melanocyte speci®c reac-
tive CD8+ T cells were identi®ed by enzyme-linked
immunospot assay after stimulation with ®ve peptides
from gp100, four peptides from MelanA/MART1,
and two peptides from tyrosinase. In selected
patients, intracellular interferon-g staining for the
detection of speci®c reactive CD8+ T cells was addi-
tionally performed. In seven of 10 patients (70%) with
actively progressive disease CD8+ T cells directed
against melanocyte epitopes were detected, whereas
only in four of 22 patients (18%) with moderate
disease activity such speci®c reactivity was found.
MelanA/MART1 peptides were immunodominant in
nine patients reacting against EAAGIGILTV and
three patients reacting against ILTVILGVL.
Intracellular interferon-g staining con®rmed the ®nd-
ings obtained by the enzyme-linked immunospot
technique. The present study supports the hypothesis
that vitiligo is a cytotoxic T lymphocyte-mediated
autoimmune disease. The presence of melanocyte-
speci®c reactive CD8+ T cells seems to be closely
related to disease activity. Key words: ELISPOT/
gp100/intracellular IFN-g staining/tyrosinase. J Invest
Dermatol 116:891±897, 2001
V
itiligo is a skin and hair disorder characterized by
circumscribed depigmented lesions of variable size
and shape, which tend to enlarge over time and in
some cases cover the whole body. This disease was
found at a prevalence of 0.4±1% of the world's
population, regardless of sex, age, and color of the skin. In 30±40%
there is a positive family history. The etiology of vitiligo is not yet
clearly known (Chakraborty et al, 1996; Maresca et al, 1997), but it
is believed by many authors that vitiligo is caused by an
autoimmune-mediated destruction of melanocytes in the epider-
mis. It has been suggested that this destruction is caused by
autoantibodies (Naughton et al, 1983; Norris et al, 1988; Baharav et
al, 1996; Hann et al, 1996; Fishman et al, 1997) or may be mediated
by cellular immunity (Le et al, 1996; Mahmoud et al, 1998).
It is an interesting ®nding that vitiligo was found more
frequently in melanoma patients (Nordlund et al, 1983; Duhra
and Ilchyshyn, 1991; Cui and Bystryn, 1995; Cavallari et al, 1996).
The prevalence of vitiligo in patients with metastatic melanoma is
2±4%, which is clearly higher than in the normal population.
Furthermore, vitiligo was observed following successful immuno-
therapy of melanoma (Lacour et al, 1992; van Elsas et al, 1999;
Overwijk et al, 1999). Particularly after immunization of melanoma
patients with peptide pulsed dendritic cells, triggering tumor
peptide-speci®c cytotoxic T lymphocyte (CTL) response, and
likewise, following high-dose interleukin-2 therapy, vitiligo-like
depigmentations were documented (Rosenberg and White, 1996;
Nestle et al, 1998). Furthermore, the presence of clonally expanded
T cells with identical BV regions has been observed in areas of
melanocyte destruction of both vitiligo-like leukoderma and
melanoma regression (Becker et al, 1999). Recently, Ogg et al
(1998) demonstrated the presence of a high frequency of skin-
homing melanocyte-speci®c CTL in the peripheral blood of seven
of nine patients with vitiligo.
This study was planned in order to correlate the occurrence of
such T cells with disease state. We established a sensitive enzyme-
linked immunospot (ELISPOT) assay for detection of CD8+ T cells
speci®c for 11 different peptides presented by melanocytes from
MelanA/MART1, tyrosinase and gp100. Furthermore, we applied
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intracellular interferon (IFN) -g staining as an additional marker for
antigen speci®city, and we examined the expression of the skin
homing marker cutaneous lymphocyte antigen (CLA) on these
cells.
MATERIALS AND METHODS
Study subjects Thirty-two patients with active to moderately
progressive vitiligo and 17 healthy asymptotic persons as control
individuals were included in this study after obtaining informed consent.
All of these study subjects were HLA-A*0201-positive.
The disease classi®cation of vitiligo was based on case history. Patients
with 10% and higher increase of vitiligo areas during the last 3 mo were
classi®ed as actively progressive, patients with less increase but signs of
progression for the last 6 mo were classi®ed as moderately progressive,
and patients without a clear increase of vitiligo areas during the last 6 mo
were classi®ed as having stable disease. Altogether, 137 patients with
vitiligo were screened (76 with stable disease, 61 with active to
moderately progressive disease; 32 of 61 were HLA-A*0201 positive).
Ten of the 32 vitiligo patients included were classi®ed as having
actively progressive disease and 22 patients as having moderately progres-
sive disease. Three of the 10 patients with actively progressive disease
had a vitiligo associated autoimmune disease, two thyroid disease and
one pernicious anemia.
The 17 control individuals were not known to have familiar dispos-
ition of any autoimmune disorder.
Lymphocyte preparation Peripheral blood mononuclear cells
(PBMC) were isolated from 100 ml heparinized blood samples by
density gradient centrifugation using Ficoll (FicoLite Linearis, Bettingen/
Main, Germany). PBMC were washed four times with phosphate-
buffered saline (PBS) in order to remove platelets. Thereafter, PBMC
were resuspended in culture medium RPMI 1640 (GIBCO BRL,
Karlsruhe, Germany) containing 24 mM NaHCO3 (Merck, Darmstadt,
Germany), 10 mM HEPES (Roth, Karlsruhe, Germany), 1.6 mM
glutamine (GIBCO BRL), 100 IU penicillin-streptomycin per ml
(GIBCO BRL) and 10% fetal bovine serum (PAA Laboratories GmbH,
4020 Linz, Austria). Cells were used for the ELISPOT assay and CLA
detection or frozen with culture medium containing 40% fetal bovine
serum and 15% dimethylsulfoxide. PBMC were thawed at 37°C, and
washed in culture medium if needed for further examinations.
Peptide synthesis and T2 cell loading The following HLA-A2
restricted peptide epitopes from melanocyte proteins were used for
stimulation in the ELISPOT assay: LLDGTATLRL (Kawakami et al,
1995) VLYRYGSFSV (Kawakami et al, 1995), ITDQVPFSV (Kawakami
et al, 1995), and YLEPGPVTA (Cox et al, 1994) from gp100. From
tyrosinase we investigated MLLAVLYCL (Wolfel et al, 1994) and
YMNGTMSQV (Wolfel et al, 1994), which can post-translationally be
modi®ed in YMDGTMSQV (Skipper et al, 1996). AAGIGILTV (Coulie
et al, 1994), ILTVILGVL (Castelli et al, 1995), EAAGIGILTV
(Kawakami et al, 1994; Romero et al, 1997) and its modi®ed form
ELAGIGILTV (Valmori et al, 1998) from MelanA/MART1. A mixture
of viral epitopes was used as a positive control: CLGGLLTMV (Lee et al,
1993), LLDFVRFMGV (White et al, 1996), and GLCTLVAML (Steven
et al, 1997) from Epstein±Barr virus (EBV), GILGFVFTL (Bednarek et
al, 1991) from in¯uenza and NLVPMVATV (Wills et al, 1996) from
cytomegalovirus (CMV). Reaction against the peptide YLLPAIVHI
(Hunt et al, 1992) from p72 helicase was assessed as unspeci®c
stimulation. Peptides and their origin are listed in Table I.
Peptides were synthesized in an automated peptide synthesizer 432A
(Applied Biosystems, Weiterstadt, Germany) following the Fmoc/tBu
strategy. Synthesis products were analyzed by high-performance liquid
chromatography (System gold, Beckman Instruments, Munich, Germany)
and MALDI-TOF mass spectrometry (G2025A, Hewlett-Packard,
Waldbronn, Germany). Peptides of less than 80% purity were puri®ed by
preparative high-performance liquid chromatography. Peptides were
dissolved in dimethylsulfoxide in a concentration of 10 mg per ml and
further diluted to a ®nal concentration of 1 mg per ml peptide with
H2O twice distilled.
For generation of stimulator cells, TAP-de®cient HLA-A2-positive T2
(Salcedo et al, 1994) were incubated with 50 mg peptide per ml for 8 h
in fetal bovine serum free culture medium. At the end of peptide
incubation T2 cells were irradiated with 170 Gy (Gammacell 1000 Elite,
MDS Nordion, Kanata, Ontario, Canada) and unbound peptide was
removed by washing with RPMI 1640 containing 10% fetal bovine
serum.
ELISPOT assay Nitrocellulose 96 well plates (MAHA 45, Millipore,
Bedford, MA) were coated with 50 ml per well human IFN-g-speci®c
antibody (20 mg per ml; Biosource, Camarillo, CA) diluted in coating
buffer (35 mM sodium bicarbonate, 15 mM sodium carbonate and
3 mM sodium acid) for 3 h at 37°C. Unbound antibody was removed
by four washing steps with PBS. Remaining protein binding sites of the
nitrocellulose plate were blocked with culture medium for 1 h at 37°C.
PBMC (50,000 per well) and peptide-loaded T2 cells (70,000 per
well) were co-cultured in triplicates in coated nitrocellulose 96 well
plates. After 40 h of incubation at 37°C, 7% CO2 cells were removed by
washing seven times with PBS containing 0.05% Tween 20 (PBS/T).
50 ml of biotinylated human IFN-g antibody (Biosource), diluted to 2 mg
per ml in PBS containing 0.5% bovine serum albumin and 0.02% sodium
azide, was used for the detection of bound IFN-g. After 3 h unbound
antibodies were removed by six washes with PBS/T and 50 ml of avidin
peroxidase complex (ABC Vectastain-Elite Kit, Vector Laboratories,
Burlingame, CA) was added. Two hours after addition of avidin
peroxidase the plate was washed three times with PBS/T and three times
with PBS. In the last washing step the complete plate was submerged in
PBS. Subsequently, the reaction was developed with 3-amino 9-ethyl-
carbazole (Sigma, St Louis, MO). After 5 min the color reaction was
stopped by rinsing with water.
Computer-assisted video image analysis was used to count spots (Carl
Zeiss Vision GmbH, Hallbergmoos, Germany). Pictures of wells were
digitized by image software. The difference of contrast was checked for
several parameters such as area, saturation, shape, slope, contrast, and
color. Only spots corresponding to the parameters determined were
counted.
The number of spots for the negative control peptide (YLLPAIVHI)
was subtracted from the number of spots for peptides. The result is taken
as the number of speci®cally reactive spots. If more spots were found in
the control sample than in the test peptide samples negative values
resulted. Values of the control collective consisting of 17 healthy persons
were taken as reference values. The cut-off level was de®ned as the
mean value of the control collective plus 2 SD. This means that 97.7%
of the control persons were de®ned as the normal range of values and
that 2.3% of control persons were expected to show elevated values.
Cut-off level was calculated separately for each peptide tested. Higher
values than de®ned by the cut-off level were regarded as representing
speci®c PBMC reactivity.
Intracellular IFN-g staining and ¯uorescence-activated cell sorter
analysis The Cyto®x/Cytoperm kit (PharMingen, San Diego, CA)
was used for intracellular IFN-g staining. Thawed cells were incubated
for 3 h in a 24 well culture plate at 37°C. This leads to adherence of
monocytes. The monocyte-free supernatant was used for further studies.
Clusters of dead cells were ®ltered through a cell strainer (40 mm;
Nylon, Falcon, Becton Dickinson, New York, NY). Peripheral blood
Table I. Peptides used for the detection of speci®cally
reactive cytotoxic T cells
Peptide sequence Protein Position Origin
KTWGQYWQV gp100 154±162 Human
ITDQVPFSV gp100 209±217 Human
YLEPGPVTA gp100 280±288 Human
LLDGTATLRL gp100 457±466 Human
VLYRYGSFSV gp100 476±485 Human
MLLAVLYCL Tyrosinase 1±9 Human
YMNGTMSQV Tyrosinase 369±377 Human
AAGIGILTV MelanA 27±35 Human
EAAGIGILTV MelanA 26±35 Human
ELAGIGILTV MelanA
(modi®ed)
26±35 Human
ILTVILGVL MelanA 32±40 Human
YLLPAIVHI p72 RNA
helicase
146±154 Human
GLCTLVAML BMLF-1 259±267 EBV
LLDFVRFMGV EBNA-6 284±293 EBV
CLGGLLTMV lmp-2 426±434 EBV
GILGFVFTL Matrix
protein
58±66 In¯uenza A
NLVPMVATV pp65 495±503 CMV
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lymphocytes (106 per ml) were incubated in 4.5 ml polystyrene tubes
(Greiner GmbH, Frickenhausen, Germany) with 106 peptide loaded T2
cells (2 h, 37°C). To stop IFN-g secretion Golgi Stop (Cyto®x/
Cytoperm Kit, PharMingen) was added (0.7 ml per ml). After another
10 h, cells were washed with PBS and stained in ¯uorescence-activated
cell sorter-buffer with 10 mg/100 ml CD8 tricolor antibody (CALTAG
Laboratories, Burlingame, CA) and 20 ml ¯uorescein isothiocyanate
labeled CLA antibody (rat IgM, PharMingen) for 30 min at 4°C. After
removing unbound antibodies cells were ®xed and permeabilized with
300 ml Cyto®x/Cytoperm solution (Cyto®x/Cytoperm Kit,
PharMingen) for 20 min at 4°C. Cells were washed twice with 1 ml of
Perm/Wash solution (Cyto®x/Cytoperm Kit, PharMingen) and stained
for 30 min in 100 ml Perm/wash solution with phycoerythrin-labeled
mouse IFN-g antibody (PharMingen) diluted to 1.5 mg per ml. Antibody
was removed by two washes and cells were resuspended in PBS. Cells
were analyzed on a FACSCalibur (Becton Dickinson, San Jose, CA)
with logarithmic ampli®cation through a viable cell gate determined by
forward and side scatter.
Culturing of PBL Fresh PBL (3 3 106) were incubated for 2 h in
serum-free culture medium with 50 mg peptide per ml followed by co-
culture with 106 autologous PBMC in a 24 well plate (Greiner GmbH,
Frickenhausen, Germany). On day 4 culture medium was supplemented
with 5% Lymphocult (Biotest, Germany) containing interleukin-2 and
other unspeci®ed T cell growth factors. T cell cultures were restimulated
weekly with 3 3 106 peptide loaded autologous PBMC per well (31 Gy
irradiated) and supplemented with Lymphocult. ELISPOT analysis was
performed 7 d after restimulation.
Statistical testing The Wilcoxon Sum-of-Ranks (Mann±Whitney) test
for comparing two unmatched samples was used for testing differences in
the ELISPOT values between different subgroups of study subjects.
p < 0.05 was statistically signi®cant.
RESULTS
Detection of melanocyte-speci®c CD8+ T lymphocytes by
ELISPOT in vitiligo patients Of the 32 patients tested 10 had
actively progressive disease and in 22 the disease progression was
moderate. In the PBMC of 11 patients (34%) T cells against the
tested epitopes were detected. Seven of them had active disease.
Four patients who reacted against the peptides had moderate disease
progression (Table II).
The most frequently encountered immunodominant epitopes
were the MelanA/MART1 peptide EAAGIGILTV and its modi-
®ed form ELAGIGILTV. PBMC of nine patients reacted against
one or both of these peptides, reaching 70±150 spots per 105 cells.
In none of the healthy individuals spot frequencies of this
magnitude were observed (Fig 1). Patients reacted signi®cantly
stronger against the epitope EAAGILGITV than healthy controls
(Wilcoxon, p = 0.0003). There was also a signi®cant difference
between patients with active disease and patients with moderate
disease progression (Wilcoxon, p = 0.02).
In two patients the peptide ILTVILGVL from MelanA/MART1
led to stimulation of T cells resulting in about 160 spots per 105
PBMC (Fig 1). This corresponded to 1±2% of the CD8+ cells in
these patients (Fig 3). Another patient also reacted against this
epitope, albeit at a lower frequency.
Three patients reacted against peptides derived from the protein
gp100. All of them also showed strong reactions against the
MelanA/MART1 peptides EAAGIGILTV and its modi®ed form
ELAGIGILTV. Four patients were found reactive against tyrosinase
peptides, they also reacted against the MelanA/MART1 peptides
EAAGIGILTV or ILTVILGVL.
The patients showing high numbers of positive spots against one
peptide, usually had speci®c reactivity against several other
peptides. In patient 32, reactivity against all four peptides deriving
from MelanA/MART1 and against three gp100 peptides and one
tyrosinase peptide was found. Patient 8 showed reactivity against
®ve peptides and patient 9 against four peptides. Altogether, six of
11 patients reacted against several peptides.
No reactivity in vitiligo patients was found against the gp100
peptide ITDQVPFSV. Weak reactivity in only one patient was
observed against the gp100 peptide YLEPGPVTA and the
tyrosinase peptide MLLAVLYCL. Only one of the control persons
studied was found to show weak reactivity against the peptides
YMNGTMSQV (tyrosinase) and ITDQVPFSV (gp100).
Although the reactivity against the peptide VLYRYGSFSV was
weak, we found a signi®cant difference between patients and
healthy donors (Wilcoxon, p = 0.004). Interestingly, 11 of the 32
patients showed a strong reaction against the viral epitope mixture
(EBV, in¯uenza A, CMV) compared with the normal individuals
(Fig 1, Wilcoxon, p = 0.003). In further experiments we stimu-
lated the strongest reacting three control persons and three patients
with CMV peptide in the same ELISPOT assay. In the patients a
much higher frequency of CMV-speci®c T cells as compared with
the control persons has been observed, suggesting that the higher
reactivity against viral antigens was mainly directed against the
CMV epitope (data not shown).
Course of the disease and development of speci®c T cell
reactivity Patients who showed strong reactions in the
ELISPOT assay and were classi®ed as having active disease were
followed in their clinical course and in their ELISPOT reactivity.
In ®ve patients acute attacks of vitiligo with disease progression
were followed by phases of stable disease without recognizable
progression, and a second blood sample has been examined by
ELISPOT assay in these patients after 3±20 mo. Patient 32 had
started ultraviolet B 311 nm irradiation therapy and had partial
repigmentation of white spots. In ELISPOT assay a clear decrease
of speci®c T cell reactivity could be demonstrated in each of the
®ve patients (Fig 2).
Intracellular IFN-g staining of PBMC con®rmed positive
reactivity Peripheral blood from the initial and second blood
puncture for additional investigations was available from three
patients reacting against melanocyte-speci®c peptides in the
ELISPOT-assay and one patient not reacting in the ELISPOT.
PBMC from these patients were tested for intracellular IFN-g
expression upon peptide stimulation. Patients 19 and 32 reacting
strongly against ILTVILGVL (MelanA/MART1) in the ELISPOT
were found to have a frequency of 1±2% of CD8+ T cells against
this peptide as shown by IFN-g production. Patient 29 with a
moderate ELISPOT frequency against the same peptide had less
IFN-g-positive CD8+ T cells in intracellular IFN-g staining. One
of the ELISPOT-negative donors had no IFN-g-positive CD8+ T
cells. Figure 3 shows intracellular IFN-g staining in patient 19 with
blood samples taken in May and August.
Lack of CLA expression in PBL reacting against melanocyte
epitopes For the same four patients whose T cells were measured
by intracellular IFN-g staining, expression of the CLA was
examined. Peripheral blood CD8+ T cells stimulated by
melanocyte peptides to produce intracellular IFN-g did not show
any difference in CLA expression as compared with control
peptides (data not shown).
DISCUSSION
Among the patients with actively progressive disease we detected
reactive T cells in seven of 10 patients (70%). In patients classi®ed as
having moderately progressive disease only four of 22 patients
(18%) had melanocyte peptide-reactive T cells. Patients without
disease progression were not included in this study. We found T
cells reactive to melanocyte peptides in about 34% of all HLA-A2-
positive patients classi®ed to have moderately to actively progres-
sive vitiligo. Thus, the frequency of cytokine-producing T cells
with speci®city for melanocyte antigens is positively correlated with
progressive vitiligo.
In a previous study (Ogg et al, 1998) addressing the T cell
response against melanocyte epitopes tetramer staining was used.
ELAGIGILTV (MelanA/MART1) -speci®c T cells were detected
in seven of nine patients studied (Ogg et al, 1998) indicating this
peptide to be immunodominant. Our study con®rms ELAGIG-
ILTV to be an immunodominant epitope also by ELISPOT, with
most speci®c T cells also recognizing the arti®cial variant
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Table II. Patient's characteristics, disease activity, and speci®c CTL reactivitya
Patient
no.
Sex/
age
Duration
of disease
(mo)
Disease
activity
% involved
skin
ELAGIG
ILTV
(MART1)
EAAGI
GILTV
(MART1)
ILTVIL
GVL
(MART1)
AAGIGI
LTV
(MART1)
LLDGT
ATLRL
(gp100)
VLYRY
GSFSV
(gp100)
KTWGQ
YWQV
(gp100)
YLEPG
PVTA
(gp100)
ITDQV
PFSV
(gp100)
YMNGT
MSQV
(tyr.)
MLLAV
LYCL
(tyr.)
4 F/30 46 Active 40 +++ +++ ± ± ± ± ± ± ± ± ±
5 F/29 54 Active 10 ± ± ± ± ± ± ± ± ± ± ±
9 F/36 120 Active 20 +++ +++ ± ± +++ + ± ± ± ± ±
15 F/56 246 Active 10 ± + ± ± ± ± ± ± ± ± ±
18 F/47 54 Active 20 ± ± ± ± ± ± ± ± ± ± ±
19 F/46 174 Active 3 ± ± +++ ± ± ± ± ± ± + ±
22 F/52 114 Active 20 ± + ± ± ± ± ± ± ± ± ±
27 F/21 48 Active 10 ± ± ± ± ± ± ± ± ± ± ±
29 F/40 78 Active 80 ± ± ++ + ± ± ± ± ± + ±
32 M/45 54 Active 15 +++ +++ +++ ++ + ++ +++ ± ± +++ ±
1 F/35 174 Moderate 40 ± ± ± ± ± ± ± ± ± ± ±
2 M/38 54 Moderate 15 ± ± ± ± ± ± ± ± ± ± ±
3 M/37 210 Moderate 10 ± ± ± ± ± ± ± ± ± ± ±
6 M/39 120 Moderate 15 ± ± ± ± ± ± ± ± ± ± ±
7 F/55 120 Moderate 20 ± ± ± ± ± ± ± ± ± ± ±
8 F/35 354 Moderate 15 ++ +++ ± ± ± ± ± + ± ++ +
10 F/48 294 Moderate 15 ± ± ± ± ± ± ± ± ± ± ±
11 F/21 174 Moderate 10 ± ± ± ± ± ± ± ± ± ± ±
12 F/65 272 Moderate 20 ± ± ± ± ± ± ± ± ± ± ±
13 F/41 282 Moderate 10 ± ± ± ± ± ± ± ± ± ± ±
14 M/52 294 Moderate 15 ± + ± ± ± ± ± ± ± ± ±
16 F/64 294 Moderate 90 ± + ± ± ± ± ± ± ± ± ±
17 F/33 306 Moderate 20 ± + ± ± ± ± ± ± ± ± ±
20 F/34 186 Moderate 25 ± ± ± ± ± ± ± ± ± ± ±
21 M/69 156 Moderate 10 ± ± ± ± ± ± ± ± ± ± ±
23 F/57 54 Moderate 90 ± ± ± ± ± ± ± ± ± ± ±
24 F/14 42 Moderate 15 ± ± ± ± ± ± ± ± ± ± ±
25 M/43 54 Moderate 3 ± ± ± ± ± ± ± ± ± ± ±
26 M/36 210 Moderate 15 ± ± ± ± ± ± ± ± ± ± ±
28 F/51 174 Moderate 5 ± ± ± ± ± ± ± ± ± ± ±
30 F/53 402 Moderate 75 ± ± ± ± ± ± ± ± ± ± ±
31 F/49 90 Moderate 8 ± ± ± ± ± ± ± ± ± ± ±
aReactions with more spots than the 97.7 percentile (mean 6 2 SD) of controls was assessed as low response (+), reactions higher than mean 6 3 SD was assessed as moderate (++), and reactions with more spots than mean 6 4
SD as strong (+++) response.
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ELAGIGILTV. Only a smaller fraction of vitiligo patients (34% of
total), however, was found to be reactive. In addition to
ELAGIGILTV, we ®nd ILTVILGVL from MelanA/MART1 as
an additional antigen for HLA-A2-restricted CD8+ T cells in three
of 32 vitiligo patients.
For the epitope EAAGIGILTV we found a signi®cant difference
between patients and healthy controls. It is an interesting observ-
ation that the frequency of melanocyte-speci®c T cells is likewise
associated with disease activity. Classi®cation of disease severity was
done in our study in advance of the immunologic investigations
and different investigators performed clinical assessment (C.C.C.)
and ELISPOT assay examinations (K.S.L.). The judgement of
disease stage could, therefore, not have been biased by knowledge
of the ELISPOT results. We did not expect to detect these clear
differences in melanocyte-speci®c T cell reactivity between patients
classi®ed as actively progressive (70%) and moderately progressive.
Also the fact that speci®c T cell reactivity decreased in patients with
stable vitiligo could mean that T cell reactivity is associated with
disease activity.
We could identify functional T cells directed against the peptides
in about 34% of our vitiligo patients, whereas Ogg et al (1998)
found tetramer binding T cells in seven of nine patients (78%). This
discrepancy may be due to one or more of the following three
reasons: First, not all cells binding to tetramers might be
functionally active and, therefore, negative in the ELISPOT
assay. As we found IFN-g producing cells it is likely that we
detected antigen-responsive memory cells. Recent reports showed
already that there are tetramer-positive cells in healthy donors that
do not express CD45RO and could not produce IFN-g in
ELISPOT assay (Pittet et al, 1999). Furthermore, in one melanoma
patient a tetramer-positive anergic T cell population has been
described (Lee et al, 1999). These ®ndings suggest that nonreactive
melanocyte-speci®c T cells may be present in vitiligo patients.
Second, the selection of study subjects in respect to the grade of
disease activity may differ between both studies with a higher
percentage of highly active vitiligo in the Ogg et al (1998) study.
Third, the ELISPOT assay is not as sensitive as tetramer staining
resulting in a lower percentage of positive T cells (Pittet et al,
1999).
Whereas Ogg et al (1998) found one of six healthy donors to be
tetramer positive, only one of the 17 healthy controls in our study
reacted weakly against two of the peptides as examined by the
ELISPOT assay. This may likewise be explained by the higher
sensitivity of the tetramer technique and the fact that tetramer
binding does not demonstrate functional activity of the T cells and
IFN-g synthesis. After stimulation of T cells of healthy blood
donors with professional antigen-presenting cells such as dendritic
cells it is possible to generate MelanA-speci®c T cells (Jenne et al,
2000). Such results suggest that T cells against MelanA antigens rest
in the blood of many healthy donors. The fact that we could detect
such T cells in only one donor suggests that the frequency of these
T cells is very low or that they are naive T cells. In order to
improve the sensitivity of ELISPOT assay, we tried repeated in vitro
stimulation of PBMC in cell culture with different peptides. This
led to high ELISPOT numbers against ELAGIGILTV and
EAAGIGILTV, but not for the other peptides (data not shown);
however, after in vitro stimulation speci®c T cells against
ELAGIGILTV and EAAGIGILTV were, likewise, found in two
of ®ve healthy donors. Therefore, we did not apply repeated in vitro
stimulation with peptides further on in our experiments.
In ®ve patients with active disease the subsequent course of
disease was monitored and additional ELISPOT examinations have
been performed. In all patients active phases of vitiligo were
followed by phases of stable disease without recognizable progres-
sion. In all ®ve patients we found 3±20 mo after ®rst examination a
clear decrease of speci®c T cell reactivity in the ELISPOT assay.
One of these patients received ultraviolet B irradiation as a vitiligo
treatment after his ®rst blood puncture. In this patient, likewise, a
clear decrease of ELISPOT reactivity could be demonstrated;
however, this decrease was similar to the decrease in the other four
patients not receiving ultraviolet B irradiation and, additionally,
there was no clear decrease in his reactivity to viral epitopes.
Therefore, we have no clear evidence for the involvement of
ultraviolet B irradiation in decreasing melanocyte-speci®c T cell
reactivity.
The CLA expression of peripheral blood CD8+ T cells
stimulated by melanocyte peptides was, likewise, examined.
CLA-positive CD8+ T cells were neither found in tested blood
of the three vitiligo patients having actively progressive disease nor
in the blood of one control individual. In the other patients no
more blood from the ®rst blood puncture was available for these
investigations after performing ELISPOT examinations. Ogg et al
(1998) reported that they have found a signi®cant difference in
CLA expression by the peptide-stimulated melanocyte-speci®c
Figure 1. ELISPOT assay. The number of
peptide-speci®c reactive spots are given. The
background as seen for the control peptide
YLLPAIVHI was subtracted in order to obtain the
number of peptide-speci®c spots per 100,000
PBMC. Negative values are set to zero in this
®gure. Negative values were, however, used for
the calculation of mean values for the control
patients. The cut-off level was determined to be
the mean 6 2 SD (97.7%) of the number of spots
of control subjects. Background: Ges1=17,
Ges2=6, Ges3=3, Ges4=1, Ges5=212, Ges6=48,
Ges7=14, Ges8=39, Ges9=87, Ges10=255,
Ges11=15, Ges12=176, Ges13=24, Ges14=36,
Ges15=99, Ges16=126, Ges17=16, Pat1=9,
Pat2=25, Pat3=106, Pat4=6, Pat5=Pat6=17,
Pat7=2, Pat8=11, Pat9=55, Pat10=50, Pat11=10,
Pat12=2, Pat13=5, Pat14=51, Pat15=15,
Pat16=48, Pat17=4, Pat18=65, Pat19=57,
Pat20=14, Pat21=56, Pat22=68, Pat23=11,
Pat24=29, Pat25=13, Pat26=14, Pat27=23,
Pat28=1, Pat29=72, Pat30=178, Pat31=13,
Pat32=43, Pat33=1.
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CTL between patients and control individuals. Ogg et al (1998)
believed that lack of the skin homing receptor on the surface of
CTL might be a mechanism to prevent autoreactivity in vivo and to
control peripheral tolerance. Our ®nding of lack of CLA expression
of melanocyte-speci®c CD8+ T cells does not support any
correlation between the frequency or extent of the vitiligo and
the CLA expression on the surface of CD8+ T cells.
Several explanations may be considered for the low frequency of
sensitized T cells in 66% of our vitiligo patients. First, epitopes
other than the peptides used in this study may be attacked by T cells
inducing melanocyte eradication. These epitopes could be different
HLA-A2 restricted epitopes from the same molecules (MelanA/
MART1, tyrosinase and gp100) or, likewise, from other molecules
expressed by melanocytes, or these epitopes could be restricted to
another major histocompatibility complex molecule, for example
to HLA-B21 or HLA-Cw6, which were shown to be associated
with vitiligo (al-Fouzan et al, 1995). Second, in a number of
patients the disease may have not been active at the time point of
study and T cells responding to the MelanA/MART1 or other
melanocyte antigens may be absent from PBL in periods of stable
disease. Third, sensitive T cells might be entrapped locally at the
site of disease and cleared from PBL. Fourth, subgroups of vitiligo
may exist that are not induced by activated T cells, but by other
mechanisms destroying melanocytes, such as antibodies or natural
killer cells (Naughton et al, 1983; Norris et al, 1988; Hann and Kim,
1995; Baharav et al, 1996; Fishman et al, 1997).
Interestingly, the vitiligo patients responded signi®cantly stron-
ger than control individuals to a mixture of viral antigens, i.e., the
peptides CLGGLLTMV, LLDFVRFMGV, GLCTLVAML from
EBV, the peptide GILGFVFTL from in¯uenza and the peptide
NLVPMVATV from CMV. This is not explained by a higher
number of CD8+ T cells in patients, as neither we (data not shown)
nor others (Mozzanica et al, 1990) found a striking difference of
CD8+ cell abundance between vitiligo patients and healthy blood
donors in ¯uorescence-activated cell sorter analysis. Instead, the
higher frequency of virus-speci®c T cells in vitiligo patients point
to a role of viral infection in the pathogenesis of the disease. CMV
has been shown to enter the skin in vitiligo patients (Grimes et al,
1996). One may speculate that the immune response against the
virus could lead to the damage of melanocytes and thus trigger
vitiligo. Another possible explanation could be a direct destruction
of melanocytes by CMV.
In conclusion, MelanA/MART1 is the dominant target (epitope
EAAGIGILTV and epitope ILTVILVGVL) and tyrosinase and
gp100 are additional targets for T cell autoimmune response in
vitiligo patients. Melanocyte-speci®c reactive T cells were mainly
found in actively progressive disease, and much less in patients with
moderate disease. As not more than 70% of the patients with active
vitiligo studied responded to those epitopes, additional antigens or
presentation by other major histocompatibility complex molecules
may play a part. The present ®ndings support the hypothesis that
vitiligo is a CD8+ T cell-mediated autoimmune disease.
Figure 2. ELISPOT assay from patients with active disease
measured at two different time points. Second blood sample was
taken 3±20 mo later.
Figure 3. Representative dot plots of PBMC from patient 19
stained for CD8 and intracellular IFN-g after peptide stimulation
with MelanA/MART1 peptides ELAGIGILTV and ILTVILGVL,
and tyrosinase peptide YMNGTMSQV. Cells were gated for forward
and side scatter. Percentage is given for peptide-speci®c cells calculated
from all CD8+ cells. (A) Represents a blood sample taken in May 1999
and (B) a blood sample from August 1999.
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